Atazanavir Sulfate
Showing 1 - 25 of 1,009
Drug Interaction Trial in Ile-Ife (Nitazoxanide, "Nitazoxanide" and "atazanavir/ritonavir" separately)
Active, not recruiting
- Drug Interaction
- Nitazoxanide
- "Nitazoxanide" and "atazanavir/ritonavir" separately
-
Ile-Ife, Osun, NigeriaObafemi Awolowo University
Jan 8, 2023
Healthy Participants Trial in Miami (Atazanavir, Cobicistat, Atazanavir/Cobicistat Mini-tablet)
Completed
- Healthy Participants
- Atazanavir
- +2 more
-
Miami, FloridaLocal Institution - 0001
Oct 27, 2022
Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2 Trial in United
Recruiting
- Coronavirus Infection
- +2 more
- Drug: NA-831
- +3 more
-
Los Angeles, California
- +30 more
Jan 31, 2022
Healthy Participants Trial in Austin (Atazanavir/Cobicistat, Reyataz Atazanavir, Cobicistat)
Completed
- Healthy Participants
- Atazanavir/Cobicistat
- +2 more
-
Austin, TexasPPD Development, LP
Nov 18, 2021
Covid-19 Trial in Sagamu, Ibadan (Nitazoxanide and atazanavir/ritonavir, Standard of Care)
Terminated
- Covid-19
- Nitazoxanide and atazanavir/ritonavir
- Standard of Care
-
Sagamu, Ogun State, Nigeria
- +1 more
Feb 14, 2022
Solid Tumor, Hematological Malignancies Trial in Santa Monica (Belinostat, Atazanavir)
Recruiting
- Solid Tumor
- Hematological Malignancies
-
Santa Monica, CaliforniaJohn Wayne Cancer Institute @ Providence Saint John's Health Cen
Jan 31, 2023
COVID-19 Trial in Sao Paulo (Atazanavir, Daclatasvir 60 mg, Sofusbuvir + Daclastavir 60 mg)
Active, not recruiting
- COVID-19
- Atazanavir
- +5 more
-
Sao Paulo, SP, BrazilHospital do Coracao
Feb 25, 2022
Pharmacokinetics of Atazanavir in Special Populations
Active, not recruiting
- HIV/AIDS
- Tuberculosis
- Atazanavir 300mg/ Ritonavir 100 mg once daily
- Atazanavir 250 mg / ritonavir 80 mg
-
Cape Town, Western Cape, South Africa
- +3 more
Sep 22, 2021
HIV Infection, HIV Trial in Germany, Netherlands (raltegravir QD, atazanavir, lamivudine (or emtricitabine))
Completed
- HIV Infection
- HIV Infections
- raltegravir QD
- +2 more
-
Bonn, Germany
- +3 more
Nov 9, 2020
Hepatitis C, HIV Trial in Nijmegen (Daclatasvir, Atazanavir, Ritonavir)
Completed
- Hepatitis C
- HIV
- Daclatasvir
- +3 more
-
Nijmegen, NetherlandsCRCN, Radboud University Medical Center
Dec 4, 2020
Population Pharmacokinetics of Antiretroviral in Children
Recruiting
- Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed
- Dolutegravir
- +6 more
-
Paris, FranceCochin Hospital
Dec 9, 2021
HIV Infection Trial in Torino (maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD))
Withdrawn
- HIV Infection
- maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD)
-
Torino, ItalyUniversity of Torino
Nov 5, 2020
Drug Interaction Trial in Suru Lere (Artemether-lumefantrine, Atazanavir-ritonavir 300/100 mg)
Completed
- Drug Interaction
- Artemether-lumefantrine
- Atazanavir-ritonavir 300/100 mg
-
Suru Lere, Lagos State, NigeriaApin (Aids Prevention Initiatives in Nigeria) clinic, Lagos Univ
Aug 26, 2020
HIV Trial in Bangkok (Atazanavir)
Completed
- HIV Infections
-
Bangkok, ThailandHIV-NAT, Thai Red Cross AIDS Research Center
Jul 15, 2020
Pediatric HIV, HIV Trial in Phoenix (Boosted Atazanavir)
Completed
- Pediatric HIV
- HIV Infections
- Boosted Atazanavir
-
Phoenix, ArizonaPhoenix Children's Hospital
Apr 15, 2020
Infection, Human Immunodeficiency Virus, HIV Trial in Worldwide (Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir)
Active, not recruiting
- Infection, Human Immunodeficiency Virus
- HIV Infections
- Dolutegravir/abacavir/lamivudine FDC
- +3 more
-
Phoenix, Arizona
- +88 more
Feb 8, 2022
Bowel Preparation Trial in Nanjing (OSS, OSS+Linzess, PEG-Interferon Alfa)
Recruiting
- Bowel Preparation
- OSS
- +2 more
-
Nanjing, Jiangsu, ChinaA single-center, single-blind, randomized controlled clinical st
Oct 20, 2023
Healthy, Irritation/Irritant, Reactions Adverse Trial (NS Solution, Normal Saline, SLS)
Completed
- Healthy
- +2 more
- NS Solution
- +2 more
- (no location specified)
Nov 1, 2023